查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1462610

放射治療口腔黏膜炎的全球市場：分析 - 按治療類型、放射治療類型、口腔黏膜炎嚴重程度、最終使用者、地區和預測（截至 2030 年）

Radiotherapy Induced Oral Mucositis Treatment Market Forecasts to 2030 - Global Analysis By Treatment Type (Topical Agents, Systemic Agents and Medical Devices), Radiotherapy Type, Severity of Oral Mucositis, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

預計2023年全球放射治療口腔黏膜炎治療市場規模將達51.5億美元，預測期內年複合成長率為5.4%，2030年將達74.4億美元。

口腔黏膜炎的放射治療 (RIOM) 治療通常涉及多方面的方法，旨在控制症狀並促進癒合。這包括口腔衛生措施，例如輕輕刷牙、生理食鹽水和處方漱口水，以減少微生物生長並緩解疼痛。使用放射療法治療口腔黏膜炎在改善患者預後和提高癌症治療的耐受性方面發揮重要作用。

根據世界衛生組織 (WHO) 的數據，癌症是世界第二大死因，2018 年估計有 960 萬人死亡，美國每年有超過 40 萬人被診斷出患有口腔黏膜炎。

老年人口不斷增加

隨著老齡化，我們變得更容易受到放射治療引起的口腔併發症，從而增加了對有針對性的解決方案的需求。 RIOM 可以對接受癌症治療的老年患者的生活品質產生重大影響。隨著這一人群的持續成長，迫切需要創新的治療方法來緩解疼痛、進食和說話困難等 RIOM 症狀，並且迫切需要針對老年患者的需求進行治療方法的進展，其重要性已得到強調和重視。市場成長。

認知有限

對 RIOM 管理和預防的認知有限可能會阻礙有效的治療。患者可能無法識別早期症狀或了解預防措施的重要性，從而導致干涉延遲和症狀惡化。如果沒有適當的教育和認知，患者可能無法堅持規定的治療和生活方式的改變，從而使 RIOM 的管理更加複雜並影響治療結果。

醫療保健支出增加

由於 RIOM 治療在接受放射治療的癌症患者中普遍存在，醫療保健支出的增加正在推動對 RIOM 治療等有效治療的需求。隨著醫療保健預算的擴大，對創新治療方法解決 RIOM 的衰弱影響，例如疼痛和飲食困難。資金的增加將鼓勵新治療方法的研究。因此，醫療保健提供者將更有可能採用這些解決方案，從而加強 RIOM 治療選擇的市場，並促進腫瘤學環境中患者照護的進一步進步。

醫療基礎設施不足

醫療基礎設施不足給 RIOM 的有效治療帶來了重大挑戰。專業醫療機構和訓練有素的人員的使用機會有限可能會延遲診斷和介入。資源缺乏可能導致用於治療 RIOM 症狀的基本藥物和設備短缺，例如止痛藥和口腔衛生產品。此外，基礎設施不足可能會阻礙患者教育和後續護理，從而降低治療結果的整體品質。

COVID-19 的影響

COVID-19 的爆發對 RIOM 治療市場產生了重大影響。癌症診斷和治療的延誤以及醫療保健服務的中斷導致患者數量減少和手術推遲，影響了對 RIOM 治療的需求。此外，嚴格的感染控制措施和醫療機構內的資源重新分配進一步阻礙了市場成長。然而，遠距遠端醫療和居家照護解決方案的進步已成為緩解這些挑戰的潛在策略，即使在疫情期間也有助於繼續獲得 RIOM 治療方案。

近距離放射治療產業預計將在預測期內成為最大的產業

近距離放射治療領域預計將出現良好的成長。近距離放射治療是放射治療的一種型態，正在成為治療放射治療引起的口腔黏膜炎的一種有前途的治療方法。近距離放射治療直接向受影響區域提供定向輻射，最大限度地減少對周圍健康組織的損害。結果顯示有可能減輕 RIOM 症狀的嚴重程度並改善患者的生活品質。其功效和精確度使其成為不斷發展的 RIOM治療方法領域的重要候選者。

預計癌症治療中心領域在預測期內的年複合成長率最高。

預計癌症治療中心產業在預測期內的年複合成長率最高。在癌症治療中心使用放射療法治療口腔黏膜炎通常涉及多方面的方法，旨在控制疼痛、預防感染和促進癒合。此外，可以採用低強度雷射療法和冷凍療法等先進技術來減少發炎並促進組織修復。目的是在癌症治療期間緩解症狀、保持口腔衛生並改善患者的生活品質。

比最大的地區

由於癌症發病率上升和放射治療技術的進步，預計亞太地區在預測期內將佔據最大的市場佔有率。此外，政府的支持措施和醫療基礎設施的改善正在促進市場開拓。主要企業注重策略聯盟和產品創新，以獲得競爭優勢。總體而言，亞太地區放射治療口腔黏膜炎治療市場預計在可預見的未來將繼續成長。

年複合成長率最高的地區：

由於癌症發生率高、醫療基礎設施先進和技術進步，預計歐洲在預測期內的年複合成長率最高。該地區正在對創新放射治療技術進行大量投資。此外，有利的報銷政策和主要市場參與者的強大影響力也促進了市場的成長。人們對放射治療作為各種癌症治療選擇的有效性的認知不斷提高，進一步推動了需求。

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球放射治療口腔黏膜炎治療市場：依治療類型

  • 外用製劑
    • 止痛藥
    • 抗菌漱口水
    • 麻醉劑
    • 被覆劑
  • 全身性藥物
    • 疼痛管理藥物
    • 生長促進因子
  • 醫療設備
    • 低強度雷射治療 (LLLT)
    • 口腔冷凍治療儀

第6章全球放射治療口腔黏膜炎治療市場：依放射治療類型

  • 外部放射治療（EBRT）
  • 強度調控放射治療(IMRT)
  • 近距離放射治療
  • 質子治療
  • 立體定位放射線手術(SRS)
  • 其他放射治療類型

第7章全球口腔黏膜炎放射治療市場：依口腔黏膜炎的嚴重程度分類

  • 溫和的
  • 緩和
  • 嚴重
  • 危害生命

第8章全球放射治療口腔黏膜炎治療市場：依最終使用者分類

  • 醫院
  • 癌症治療中心
  • 門診手術中心
  • 調查機構
  • 其他最終用戶

第9章全球放射治療口腔黏膜炎治療市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東/非洲

第10章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司概況

  • The 3M Company
  • GlaxoSmithKline PLC
  • Sun Pharmaceutical Industries Limited
  • Fagron Group BV
  • Pfizer Inc.
  • Merck & Co. Inc.
  • Eusa Pharma
  • Valeant Pharmaceuticals International Inc.
  • Eisai Corporation
  • Amgen Inc.
  • Galera Therapeutics Inc.
  • EpicentRx
  • Soligenix Inc.
  • Cellceutix Corporation
  • GI Solutions Group
Product Code: SMRC25661

According to Stratistics MRC, the Global Radiotherapy Induced Oral Mucositis Treatment Market is accounted for $5.15 billion in 2023 and is expected to reach $7.44 billion by 2030 growing at a CAGR of 5.4% during the forecast period. Radiotherapy-induced oral mucositis (RIOM) treatment typically involves a multifaceted approach aimed at managing symptoms and promoting healing. These may include oral hygiene measures like gentle brushing and rinsing with saline solution or prescribed mouthwashes to reduce microbial growth and alleviate pain. Radiotherapy-induced oral mucositis treatment plays a crucial role in improving patient outcomes and enhancing the tolerability of cancer therapy.

According to the World Health Organization (WHO), cancer is the second leading cause of death globally, with an estimated 9.6 million deaths in 2018 and over 400,000 people in the US are estimated to receive an oral mucositis diagnosis each year.

Market Dynamics:

Driver:

Expanding geriatric population

With age, individuals become more susceptible to oral complications from radiotherapy, exacerbating the need for targeted solutions. RIOM can significantly impact the quality of life for elderly patients undergoing cancer treatment. As this demographic continues to grow, there is a pressing need for innovative therapies that alleviate RIOM symptoms, such as pain and difficulty in eating and speaking, thus highlighting the importance of advancing treatments tailored to meet the needs of older patients, thereby, driving the market growth.

Restraint:

Limited awareness

Limited awareness about the management and prevention of RIOM can hinder effective treatment. Patients may not recognize early symptoms or understand the importance of preventive measures, leading to delayed intervention and exacerbation of symptoms. Without proper education and awareness, patients may not adhere to prescribed treatments or lifestyle modifications, further complicating the management of RIOM and potentially compromising treatment outcomes.

Opportunity:

Rising healthcare expenditure

Rising healthcare expenditure drives demand for effective treatments like RIOM treatment due to its prevalence in cancer patients undergoing radiation therapy. With healthcare budgets expanding, there's greater investment in innovative therapies addressing RIOM's debilitating effects, such as pain and difficulty eating. This increased funding facilitates research into novel treatment modalities. Consequently, healthcare providers are more inclined to adopt these solutions, bolstering the market for RIOM treatment options and driving further advancements in patient care within oncology settings.

Threat:

Inadequate healthcare infrastructure

Inadequate healthcare infrastructure poses significant challenges to effective treatment of RIOM. Limited access to specialized healthcare facilities and trained personnel can delay diagnosis and intervention. Insufficient resources may lead to shortages of essential medications and equipment necessary for managing RIOM symptoms, such as pain relievers and oral hygiene products. Additionally, inadequate infrastructure may hinder patient education and follow-up care, reducing the overall quality of treatment outcomes.

Covid-19 Impact

The covid-19 pandemic has significantly impacted the RIOM treatment market. Delays in cancer diagnoses and treatments, along with disruptions in healthcare services, have led to reduced patient volumes and procedural postponements, affecting the demand for RIOM treatments. Additionally, stringent infection control measures and resource reallocations within healthcare facilities have further impeded market growth. However, advancements in telemedicine and homecare solutions have emerged as potential strategies to mitigate these challenges, facilitating continued access to RIOM treatment options amidst the pandemic.

The brachytherapy segment is expected to be the largest during the forecast period

The brachytherapy segment is estimated to have a lucrative growth. Brachytherapy, a form of radiotherapy, is emerging as a promising treatment for radiotherapy induced oral mucositis. Brachytherapy delivers targeted radiation directly to the affected area, minimizing damage to surrounding healthy tissue. As a result, it shows potential in reducing the severity of RIOM symptoms and improving patient quality of life. Its efficacy and precision make it a significant contender in the evolving landscape of RIOM treatment modalities.

The cancer treatment centers segment is expected to have the highest CAGR during the forecast period

The cancer treatment centers segment is anticipated to witness the highest CAGR growth during the forecast period. Radiotherapy-induced oral mucositis treatment in cancer treatment centers typically involves a multifaceted approach aimed at managing pain, preventing infection, and promoting healing. Additionally, advanced techniques like low-level laser therapy or cryotherapy may be employed to reduce inflammation and promote tissue repair. The goal is to mitigate symptoms, maintain oral hygiene, and improve the patient's quality of life during cancer treatment.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to rising cancer incidence and advancements in radiotherapy techniques. Moreover, supportive government initiatives and improving healthcare infrastructure are fostering market development. Key players are focusing on strategic collaborations and product innovations to gain a competitive edge. Overall, the Asia Pacific radiotherapy induced oral mucositis treatment market is poised for continuous growth in the foreseeable future.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, owing to high prevalence of cancer, advanced healthcare infrastructure, and technological advancements. The market sees significant investments in innovative radiotherapy technologies in the region. Moreover, favourable reimbursement policies and a strong presence of key market players contribute to market growth. Increasing awareness about the efficacy of radiotherapy as a treatment option for various cancers, further fuels demand.

Key players in the market

Some of the key players profiled in the Radiotherapy Induced Oral Mucositis Treatment Market include The 3M Company, GlaxoSmithKline PLC, Sun Pharmaceutical Industries Limited, Fagron Group BV, Pfizer Inc., Merck & Co. Inc., Eusa Pharma, Valeant Pharmaceuticals International Inc., Eisai Corporation, Amgen Inc., Galera Therapeutics Inc., EpicentRx, Soligenix Inc., Cellceutix Corporation and GI Solutions Group.

Key Developments:

In March 2023, EpicentRx announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to RRx-001, a direct NLRP3 inhibitor and Nrf2 upregulator with anti-inflammatory and antioxidant properties, for the prevention/attenuation of severe oral mucositis in chemotherapy and radiation-treated head & neck cancer patients.

In February 2023, Galera Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and granted priority review to the New Drug Application (NDA) for avasopasem manganese for radiotherapy (RT)-induced severe oral mucositis (SOM) in patients with head and neck cancer (HNC) undergoing standard-of-care treatment.

Treatment Types Covered:

  • Topical Agents
  • Systemic Agents
  • Medical Devices

Radiotherapy Types Covered:

  • External Beam Radiation Therapy (EBRT)
  • Intensity-Modulated Radiation Therapy (IMRT)
  • Brachytherapy
  • Proton Therapy
  • Stereotactic Radiosurgery (SRS)
  • Other Radiotherapy Types

Severity of Oral Mucositis Covered:

  • Mild
  • Moderate
  • Severe
  • Life-threatening

End Users Covered:

  • Hospitals
  • Cancer Treatment Centers
  • Ambulatory Surgical Centers
  • Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Radiotherapy Induced Oral Mucositis Treatment Market, By Treatment Type

  • 5.1 Introduction
  • 5.2 Topical Agents
    • 5.2.1 Analgesics
    • 5.2.2 Antimicrobial Mouthwash
    • 5.2.3 Anesthetics
    • 5.2.4 Coating Agents
  • 5.3 Systemic Agents
    • 5.3.1 Pain Management Drugs
    • 5.3.2 Growth Factors
  • 5.4 Medical Devices
    • 5.4.1 Low-Level Laser Therapy (LLLT)
    • 5.4.2 Oral Cryotherapy Devices

6 Global Radiotherapy Induced Oral Mucositis Treatment Market, By Radiotherapy Type

  • 6.1 Introduction
  • 6.2 External Beam Radiation Therapy (EBRT)
  • 6.3 Intensity-Modulated Radiation Therapy (IMRT)
  • 6.4 Brachytherapy
  • 6.5 Proton Therapy
  • 6.6 Stereotactic Radiosurgery (SRS)
  • 6.7 Other Radiotherapy Types

7 Global Radiotherapy Induced Oral Mucositis Treatment Market, By Severity of Oral Mucositis

  • 7.1 Introduction
  • 7.2 Mild
  • 7.3 Moderate
  • 7.4 Severe
  • 7.5 Life-threatening

8 Global Radiotherapy Induced Oral Mucositis Treatment Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals
  • 8.3 Cancer Treatment Centers
  • 8.4 Ambulatory Surgical Centers
  • 8.5 Research Institutes
  • 8.6 Other End Users

9 Global Radiotherapy Induced Oral Mucositis Treatment Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 The 3M Company
  • 11.2 GlaxoSmithKline PLC
  • 11.3 Sun Pharmaceutical Industries Limited
  • 11.4 Fagron Group BV
  • 11.5 Pfizer Inc.
  • 11.6 Merck & Co. Inc.
  • 11.7 Eusa Pharma
  • 11.8 Valeant Pharmaceuticals International Inc.
  • 11.9 Eisai Corporation
  • 11.10 Amgen Inc.
  • 11.11 Galera Therapeutics Inc.
  • 11.12 EpicentRx
  • 11.13 Soligenix Inc.
  • 11.14 Cellceutix Corporation
  • 11.15 GI Solutions Group

List of Tables

  • Table 1 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Treatment Type (2021-2030) ($MN)
  • Table 3 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Topical Agents (2021-2030) ($MN)
  • Table 4 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Analgesics (2021-2030) ($MN)
  • Table 5 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Antimicrobial Mouthwash (2021-2030) ($MN)
  • Table 6 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Anesthetics (2021-2030) ($MN)
  • Table 7 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Coating Agents (2021-2030) ($MN)
  • Table 8 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Systemic Agents (2021-2030) ($MN)
  • Table 9 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Pain Management Drugs (2021-2030) ($MN)
  • Table 10 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Growth Factors (2021-2030) ($MN)
  • Table 11 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Medical Devices (2021-2030) ($MN)
  • Table 12 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Low-Level Laser Therapy (LLLT) (2021-2030) ($MN)
  • Table 13 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Oral Cryotherapy Devices (2021-2030) ($MN)
  • Table 14 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Radiotherapy Type (2021-2030) ($MN)
  • Table 15 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By External Beam Radiation Therapy (EBRT) (2021-2030) ($MN)
  • Table 16 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Intensity-Modulated Radiation Therapy (IMRT) (2021-2030) ($MN)
  • Table 17 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Brachytherapy (2021-2030) ($MN)
  • Table 18 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Proton Therapy (2021-2030) ($MN)
  • Table 19 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Stereotactic Radiosurgery (SRS) (2021-2030) ($MN)
  • Table 20 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Other Radiotherapy Types (2021-2030) ($MN)
  • Table 21 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Severity of Oral Mucositis (2021-2030) ($MN)
  • Table 22 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Mild (2021-2030) ($MN)
  • Table 23 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Moderate (2021-2030) ($MN)
  • Table 24 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Severe (2021-2030) ($MN)
  • Table 25 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Life-threatening (2021-2030) ($MN)
  • Table 26 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 27 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 28 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
  • Table 29 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 30 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 31 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.